Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
A composition comprising recombinant iduronate-2-sulfatase (IDS) and a method for producing a purified recombinant IDS are provided. The glycosylation pattern and formylglycine content of the IDS composition are different from those of ELAPRASE® and have superior pharmaceutical efficacy and are safer than the conventional agent and thus can be effectively used for the therapy of Hunter syndrome.
1. A method for preparing a composition comprising an iduronate-2-sulfatase (IDS) having the amino acid sequence of SEQ ID NO: 1, wherein a molar ratio of the IDS of which amino acid at position 59 in the SEQ ID NO: 1 is formylglycine (FGly) is 65% or higher of the total amount of the IDS in the composition, said method comprising:
(a) subjecting a culture of a host cell to an anion exchange chromatography, wherein the host cell is transfected with a gene encoding an IDS of SEQ ID NO: 1 and the culture contains the IDS, comprising eluting the IDS with a first elution buffer of pH 5.5-7.5;
(b) subjecting the eluant obtained in (a) to a hydrophobic chromatography, comprising eluting the IDS with a second elution buffer of pH 5.0-7.0; and
(c) subjecting the eluant obtained in (b) to a cation exchange chromatography, comprising eluting the IDS with a third elution buffer of pH 4.0-6.0 to obtain the composition.
2. The method of claim 1 , wherein the host cell is a Chinese hamster ovary cell.
3. The method of claim 1 , wherein the IDS is a recombinant human IDS.
4. The method of claim 1 , further comprising a step of lowering pH of the eluant obtained in step (b) to a range of pH 3.0-4.0.
5. The method of claim 1 , further comprising
(d) subjecting the eluant obtained in (c) to an affinity chromatography, comprising eluting the IDS using a fourth elution buffer of pH 6.0-8.0.
6. The method of claim 1 , wherein the first elution buffer comprises sodium chloride.
7. The method of claim 1 , wherein the second elution buffer contains glycerol.
8. The method of claim 1 , wherein the third elution buffer contains glycerol.
9. The method of claim 1 , wherein the composition comprising the IDS has a host cell derived DNA content of 0.1 ng/mg or less based on the total amount of the composition.
10. The method of claim 1 , wherein the composition comprising the IDS has a host cell derived protein content of 20 ng/mg or less based on the total amount of the composition.
11. The method of claim 1 , wherein the composition comprising the IDS has an isoelectric point of 3.5 or less.
12. The method of claim 1 , wherein the molar ratio of the IDS of which amino acid at position 59 in the SEQ ID NO: 1 is FGly is 75% or higher of the total amount of the IDS in the composition.
13. The method of claim 1 , wherein a purity of the IDS in the composition is 98% or higher, determined by SE-HPLC.
14. A composition comprising a purified recombinant human iduronate-2-sulfatase (IDS) having the amino acid sequence of SEQ ID NO: 1, wherein a molar ratio of the IDS in which the amino acid residue at position 59 in the IDS amino acid sequence is formylglycine (FGly) is 65% or higher, and wherein the composition contains 20 ng/mg or less of host cell derived proteins, based on the total amount of the composition.
15. The composition of claim 14 , wherein the molar ratio of the IDS in which the amino acid residue at position 59 is FGly is 75% or higher.
16. The composition of claim 14 , which has an isoelectric point of 3.5 or less.
17. A method for producing a formulation comprising an iduronate-2-sulfatase (IDS) having the amino acid sequence of SEQ ID NO: 1, wherein a molar ratio of the IDS of which amino acid at position 59 in the SEQ ID NO: 1 is formylglycine (FGly) is 65% or higher of the total amount of the IDS in the composition, said method comprising:
(a) subjecting a culture of a host cell to an anion exchange chromatography, wherein the host cell is transfected with a gene encoding an IDS of SEQ ID NO: 1 and the culture contains the IDS, comprising eluting the IDS with a first elution buffer of pH 5.5-7.5;
(b) subjecting the eluant obtained in (a) to a hydrophobic chromatography, comprising eluting the IDS with a second elution buffer of pH 5.0-7.0; and
(c) subjecting the eluant obtained in (b) to a cation exchange chromatography, comprising eluting the IDS with a third elution buffer of pH 4.0-6.0 to obtain a purified IDS; and
(d) combining the purified IDS with a pharmaceutically acceptable carrier to obtain the formulation.
18. The method of claim 17 , wherein the pharmaceutically acceptable carrier is a buffer comprising a distilled water, polysorbate 20, sodium phosphate monobasic monohydrate, sodium phosphate dibasic heptahydrate, and sodium chloride.
19. The method of claim 17 , wherein the formulation further comprises a buffer containing a distilled water, polysorbate 20, sodium phosphate monobasic monohydrate, sodium phosphate dibasic heptahydrate, and sodium chloride.
20. The method of claim 1 , wherein the first elution buffer in step (a) has a pH of 7.0±0.3.
21. The method of claim 1 , wherein the second elution buffer in step (b) has a pH of 5.5±0.2.
22. The method of claim 1 , wherein the third elution buffer in step (c) has a pH of 5.3±0.2.
23. The method of claim 3 , wherein the pH of the eluant obtained in step (b) is lowered to 3.7±0.05.
24. The method of claim 4 , wherein the fourth elution buffer has a pH of 6.2±0.2.
25. The method of claim 17 , wherein the first elution buffer in step (a) has a pH of 7.0±0.3.
26. The method of claim 17 , wherein the second elution buffer in step (b) has a pH of 5.5±0.2.
27. The method of claim 17 , wherein the third elution buffer in step (c) has a pH of 5.3±0.2.